Publications by authors named "Laura Sit"

Claim this Profile
M
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
Michael J Campbell, Denise M Wolf, Christina Yau, Lamorna Brown-Swigart, Julie Wulfkuhle, Laura Sit

Cell Rep Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
Rosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, Lamorna Brown-Swigart, Christina Yau, Laura Sit

Cell Rep Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
Denise M Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Rosa I Gallagher, Laura Sit

Cancer Cell· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Lajos Pusztai, Christina Yau, Denise M Wolf, Hyo S Han, Lili Du, Laura Sit

Cancer Cell· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study.
Martin W Schoen, Ethan Basch, Lori L Hudson, Arlene E Chung, Tito R Mendoza, Laura Sit

JMIR Hum Factors· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.
Ethan Basch, Allison M Deal, Mark G Kris, Howard I Scher, Clifford A Hudis, Laura Sit

J Clin Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Ethan Basch, Bryce B Reeve, Sandra A Mitchell, Steven B Clauser, Lori M Minasian, Laura Sit

J Natl Cancer Inst· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Sumita S Bhatta, Kristen E Wroblewski, Kelly L Agarwal, Laura Sit, Ezra E W Cohen

Oncologist· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Jennifer L Hay, Thomas M Atkinson, Bryce B Reeve, Sandra A Mitchell, Tito R Mendoza, Laura Sit

Qual Life Res· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.
Karen A Autio, Antonia V Bennett, Xiaoyu Jia, Michael Fruscione, Tomasz M Beer, Laura Sit

J Oncol Pract· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy.
Timothy J Judson, Antonia V Bennett, Lauren J Rogak, Laura Sit, Allison Barz

J Clin Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.
Thomas M Atkinson, Susan Halabi, Antonia V Bennett, Lauren Rogak, Laura Sit

Pain Med· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability of adverse symptom event reporting by clinicians.
Thomas M Atkinson, Yuelin Li, Charles W Coffey, Laura Sit, Mary Shaw

Qual Life Res· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electronic toxicity monitoring and patient-reported outcomes.
Ethan M Basch, Bryce B Reeve, Sandra A Mitchell, Stephen B Clauser, Lori Minasian, Laura Sit

Cancer J· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI).
Thomas M Atkinson, Barry D Rosenfeld, Laura Sit, Tito R Mendoza, Mike Fruscione

J Pain Symptom Manage· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Deborah Watkins Bruner, Laura J Hanisch, Bryce B Reeve, Andy M Trotti, Deborah Schrag, Laura Sit

Transl Behav Med· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations.
Thomas M Atkinson, Tito R Mendoza, Laura Sit, Steven Passik, Howard I Scher

Pain Med· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.
Ethan Basch, Xiaoyu Jia, Glenn Heller, Allison Barz, Laura Sit

J Natl Cancer Inst· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Michael L Maitland, Kristen E Kasza, Theodore Karrison, Kristin Moshier, Laura Sit

Clin Cancer Res· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis